Convidecia – Single shot for faster protectionName：Recombinant COVID-19 Vaccine（Adenovirus Type 5 Vector）
Convidecia is a Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) co-developed by CanSinoBIO and the Beijing Institute of Biotechnology, Academy of Military Medical Sciences. Convidecia received conditional approval by China NMPA on Feb 25th, 2021.
The main features are as follows:
Single shot for quick protection 14 days after vaccination
14 Days: 68.83% effective in preventing all symptomatic COVID-19 disease and 95.47% effective in preventing severe COVID-19 disease
28 Days: 65.28% effective in preventing all symptomatic COVID-19 disease and 90.07% effective in preventing severe COVID-19 disease
Induces significant humoral and cellular immune response, providing dual protection
Reduces the cost and workload for vaccination
Increases the compliance for vaccination
SARS-CoV-2 is a positive-sense, single-stranded RNA virus. It is a virus of the species severe acute respiratory syndrome–related coronavirus (SARSr-CoV). The virus primarily spreads between people through close contact and via respiratory droplets produced from coughs or sneezes. It mainly enters human cells by binding to the angiotensin converting enzyme 2 (ACE2).
Antibodies directed to S protein can neutralize the virus and prevent infection. S protein is the major target of neutralizing antibodies to coronaviruses.
SARS-COV-2 Centers for Disease Control and Prevention/AFP/File
SARS-COV-2 infects host cells through the binding of its spike protein to host cell surface receptor ACE2 / A New Map Catalogs the Effects of Coronavirus Mutations
The spread of SARS-COV-2 is mainly through COVID-19 patients and asymptomatic carriers. People who get infected with SARS-COV-2 can spread it during the incubation period and are most contagious 5 days after the symptom onset. COVID-19 is primarily transmitted from person-to-person through respiratory droplets and close contact and can also be transmitted through touching contaminated objects and aerosol. 
Anyone can get sick with COVID-19 and become seriously ill or die at any age. The most common symptoms of COVID-19 are fever, dry cough and fatigue. Among those who develop symptoms, most (about 80%) recover from the disease without needing hospital treatment. About 15% become seriously ill and require oxygen and 5% become critically ill and need intensive care. People of all ages who experience fever and/or cough associated with difficulty breathing or shortness of breath, chest pain or pressure, or loss of speech or movement should seek medical care immediately.
COVID-19 is a new acute respiratory infectious disease and has become a public health emergency of international concern. With strict prevention and control and medical treatment, China has successfully contained COVID-19 domestically, with only occasional localized outbreaks and few imported cases. However, as the pandemic continues to spread globally, China still faces the risk of COVID-19 outbreaks before mass immune protection is established.
The adenovirus-based viral vector vaccine technology
• Genes related to virus replication are removed from the adenovirus type 5 vector to make the vector replication defective in human bodies.
• The gene encoding COVID-19 spike protein (S protein) is inserted at the same location.
• Adenovirus type 5 vector delivers the gene sequence of S protein into human cells.
• Having entered the cells, the gene is transcribed to express the S protein, which serves as an antigen that triggers the host’s immune response.
Global multicenter clinical study
Launched in September 2020, the phase III clinical trial of Convidecia is a global multicenter, randomized, double-blind, placebo-controlled, adaptive designed phase Ⅲ clinical trial to evaluate the efficacy, safety and immunogenicity of Convidecia in adults 18 years of age and older. All participants receive a single dose of either Convidecia or a placebo vaccine on Day 0 and are followed to monitor vaccine candidate efficacy and incidence of SAE for a duration of 52 weeks. The primary objective is to measure the efficacy of Ad5-nCoV in preventing virologically confirmed (PCR positive) symptomatic COVID-19 disease, regardless of severity, occurring 28 days to 52 weeks after vaccination. COVID-19 rates in Convidecia group will be compared with COVID-19 rates in the control group. The primary safety objective is to evaluate the incidence of SAE and medically attended adverse events within 52 weeks after vaccination in all participants.
The phase III clinical trial of Ad5-nCoV has vaccinated more than 40,000 volunteers in 78 clinical trial sites across five countries over three continents, and is led by global principal investigator (“PI”), global co-PI and country co-PI from seven countries, and strictly complies with high ethical standards and rigorous scientific principles.
Related resources and websites